Warfarin or Acenocoumarol: Which Is better in the Management of Oral Anticoagulants?

Summary

Warfarin is employed more frequently than acenocoumarol because of its longer half-life (36 h), theoretically providing more stable anticoagulation, and avoiding factor VII fluctuations that potentially occur during acenocoumarol treatment (half-life 10 h).

The aim of our study was to compare acenocoumarol with warfarin in the same group of 103 patients who started oral anticoagulation with acenocoumarol and then changed to warfarin. In these patients we compared the previous period of six months on acenocoumarol treatment (July-December 1996) with a new six-month period on warfarin (July-December 1997). We wished to know whether warfarin could improve the quality and the stability of oral anticoagulation of our patients and whether there was a difference between the two drugs in the weekly mean dose per patient. Moreover in order to detect the possible daily fluctuation of factor VII, we evaluated a further group of 54 patients. A subgroup of these patients was treated with warfarin while another received acenocoumarol.

In the first group of patients, 1,158 and 1,064 PTs were carried out with acenocoumarol and warfarin, respectively. The percentage of PTs in the therapeutic range was 59% with acenocoumarol and 62% with warfarin (p = 0.4). The mean number of visits per patient was 12 and 11, and the mean number of visits in the therapeutic range was 7 and 7, respectively. The last check in file method did not show any difference between the two drugs. Overdose states were 51 (4.4%) with acenocoumarol and 30 (2.8%) with warfarin (p = 0.4). A good correlation (r = 0.92) was found between the acenocoumarol and the warfarin weekly mean dose. The mean warfarin/acenocoumarol weekly dose ratio was 2.08 (range: 1.25-3.30; CI 95%: 1.99-2.16).

In the second group of patients, factor VII levels with both drugs were higher 24 h after administration than 16 h after, showing that their daily fluctuation was independent of the drug’s half-life, since factor VII levels in patients with a low vitamin K intake were not increased.

Our results showed that warfarin did not appear to be better than acenocoumarol in the performance of an Anticoagulation Clinic in terms of PTs within the therapeutic range per patient. It seems that the behaviour of factor VII was affected by the intake of vitamin K rather than by the short half-life of acenocoumarol.

• References

• 1 Hirsh J. Oral anticoagulants drugs.. N Eng J Med 1991; 324: 1865-75.
• 2 Suttie JW. The biochemical basis of warfarin therapy.. In the new dimensions of warfarin prophylaxis (Wessler S. Becker CG. Nemerson Y. ed.). Adv Exp Med Bol. 1987. pp 3-16.
• 3 Breed WPM, van Hoof JP, Haanen C. A comparative study concerning the stability of the anticoagulant effect of acenocoumarol and phenprocoumon.. Acta Med Scand 1969; 186: 283-8.
• 4 Fekkes N, De Jonge H, Veltkamp JJ, Bieger R, Loeliger A. Comparative study of the clinical effect of Acenocoumarol (Sintrom) and Phenprocoumon (Marcoumar) in myocardial infarction and angina pectoris.. Acta Med Scand 1971; 190: 535-40.
• 5 Ensor RE, Peters HR. Experience with the anticoagulant Marcoumar.. Ann Int Med 1957; 47: 731-43.
• 6 Rodman T, Pastor BH, Resnick ME. Phenprocoumon, Diphenadione, Warfarin and Bihydroxycoumarin: a comparative study.. Am J Med Sci 1964; 247: 655-64.
• 7 Hemker HC, Frank HLL. The mechanism of action of oral anticoagulants and its consequences for the practice of oral anticoagulation.. Haemostasis 1985; 15: 263-70.
• 8 Thijssen HHW, Hamulyak K, Willigers H. 4 – Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationship.. Thromb Haemost 1988; 60: 35-8.
• 9 Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG. A comparative study on the quality of oral anticoagulant therapy (Warfarin versus Acenocoumarol).. Thromb Haemost 1994; 71: 188-91.
• 10 Federazione Centri Sorveglianza Anticoagulati.. Nuova guida alla terapia con Anticoagulanti Orali. Raccomandazioni della Federazione Centri Sorveglianza Anticoagulati (FCSA).. Aprile. 1996 pp 9-84.
• 11 Manotti C, Quintavalla R, Pattacini C, Pini M. Seasonal variation of oral anticoagulant effect.. Thromb Haemost 1994; 71: 802-3.
• 12 van den Besselaar AMHP, Felix D, van der Meer JM, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Netherlands.. Am J Clin Pathol 1988; 90: 685-90.
• 13 van den Besselaar AMHP. Recommended method for reporting therapeutic control of oral anticoagulant therapy.. Thromb Haemost 1990; 63: 316-7.
• 14 Barcellona D, Biondi G, Vannini ML, Marongiu F. Comparison between recombinant and rabbit thromboplastin in the management of patients on oral anticoagulant therapy.. Thromb Haemost 1996; 75: 488-90.
• 15 Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal.. Haemostasis 1993; 23: 77-82.
• 16 Marongiu F, Sorano GG, Conti M, Mameli G, Biondi G, Licheri D, Bale-strieri A.. Known vitamin K intake and management of poorly controlled oral anticoagulant therapy.. Lancet 1992; 340: 545-6.
• 17 Shearer MJ. Vitamin K, . Lancet 1995; 345: 229-34.
• 18 Palareti G, Leali N, Coccheri S, Poggi M. et al. On behalf of the Italian Study on Complications of oral anticoagulant therapy. Bleeding complications of oral anticoagulant treatment an inception-cohort, prospective collaborative study (ISCOAT).. Lancet 1996; 348: 423-8.